Accelerated growth for AbbVie's Humira lifts 3rd-quarter results above expectation The Pharma Letter AbbVie's partnership with Biogen Idec (Nasdaq: BIIB) on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that ... |
